secwatch.observer — SEC 8-K summary
======================================

Issuer:     Processa Pharmaceuticals, Inc. (PCSA)
CIK:        0001533743
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001493152-23-027122
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Processa Pharmaceuticals appoints George Ng as CEO; COO Floyd to resign Aug 31
------------------------------------------------------------------------------

- George Ng appointed CEO and director effective Aug 8, 2023; previously president/COO of Calidi Biotherapeutics.
- David Young steps down as CEO but remains President of R&D and board member; focuses on NGC drugs.
- R. Michael Floyd resigns as COO by mutual agreement, effective August 31, 2023.
- Ng receives $400k base salary, up to $100k bonus, and 800k RSUs (400k time-vest, 400k performance-based).
- Ng previously led Scilex through $140M financing, FDA approval, and sale; holds JD from Notre Dame.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533743/000149315223027122/0001493152-23-027122-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533743/000149315223027122/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-027122

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer